Text Size

Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

This study is currently recruiting participants.
Verified November 2012 by National Cancer Institute (NCI)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00899990
First received: May 9, 2009
Last updated: November 22, 2012
Last verified: November 2012
History of Changes
  Purpose

RATIONALE: Collecting and storing samples of tumor tissue, bone marrow, and blood from patients with cancer to test in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing samples of tumor tissue, bone marrow, and blood from patients with Ewing sarcoma.


Condition Intervention
Sarcoma
 Other: biologic sample preservation procedure
Other: medical chart review

Study Type: Observational
Official Title: A COG Study for Collecting and Banking Ewing Sarcoma Specimens

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Banking of biological specimens, including associated demographic and clinical data [ Designated as safety issue: No ]

Study Start Date: February 2008
Detailed Description:

OBJECTIVES:

  • Collect biological specimens, including associated demographic and clinical data, from patients with Ewing sarcoma.
  • Provide a repository for long-term storage of Ewing sarcoma-related biological materials.
  • Make collected specimens available to qualified researchers to understand the biology of Ewing sarcoma and correlate these results with demographic and clinical data.

OUTLINE: This is a multicenter study.

Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived.

Patients who are not enrolled on a therapeutic clinical trial are followed annually.

PROJECTED ACCRUAL: Not specified.

  Eligibility

Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of Ewing sarcoma, including peripheral primitive neuroectodermal tumor and Askin tumor

    • Newly diagnosed or recurrent disease

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00899990

  Show 156 Study Locations
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
Study Chair: Stephen Lessnick, MD, PhD University of Utah
Study Chair: Richard Gorlick, MD Children's Hospital at Montefiore
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00899990     History of Changes
Other Study ID Numbers: CDR0000544202, COG-AEWS07B1
Study First Received: May 9, 2009
Last Updated: November 22, 2012
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
localized Ewing sarcoma/peripheral primitive neuroectodermal tumor
metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor
recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
Askin tumor

Additional relevant MeSH terms:
Neuroectodermal Tumors, Primitive
Sarcoma, Ewing's
Neuroectodermal Tumors, Primitive, Peripheral
Sarcoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
 Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue

ClinicalTrials.gov processed this record on May 19, 2013